ViiV agrees to expand access to long-acting HIV PrEP
Under a new agreement, licenced manufacturers will be able to…
Under a new agreement, licenced manufacturers will be able to supply generic versions of ViiV’s long-acting cabotegravir HIV pre-exposure prophylaxis (PrEP) medication to developing nations.